Hydroxychloroquine clinical trial for new coronary pneumonia approved in the US by the US-FDA According to a recent report from the US Newsweek website, Novartis Pharmaceuticals, headquartered in Switzerland, said it has reached an agreement with the US Food and Drug Administration to launch a new anti-malarial drug hydroxychloroquine treatment in the United States Clinical trials of hospitalized patients with pneumonia. The entire trial involved 400 patients to assess the effectiveness of the drug. According to the US Centers for Disease Control and Prevention, there are currently no effective therapies and vaccines that can cure new coronary pneumonia. In recent weeks, a number of clinical tests have been conducted around the world to determine whether hydroxychloroquine can relieve some symptoms of new coronary pneumonia, but the results obtained are very different. US President Donald Trump previously said in a White House briefing and Twitter that the drug has...
Comments
Post a Comment